Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Semaglutide, a glucagon-like peptide-1 receptor agonist, has demonstrated clinically important weight loss effects in patients with type 2 diabetes. However, its effects on sustained weight loss among individuals without diabetes remains unclear. Our objective was to examine the long-term efficacy and safety of semaglutide use for weight loss among individuals with overweight/obesity and without diabetes. MEDLINE, Embase, and the Cochrane Libraries were systematically searched to identify randomized controlled trials (RCTs) that randomized participants with overweight/obesity but without diabetes to once-weekly 2.4 mg subcutaneous semaglutide versus placebo with follow-up of at least 68 weeks.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Areesha Moiz, Jeremy Y. Levett, Kristian B. Filion, Katya Peri, Pauline Reynier, Mark J. Eisenberg Source Type: research
More News: Cardiology | Databases & Libraries | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Heart | Obesity | Weight Loss